Enoda Cellworks key facts
- Developer of synthetic biology-based cell therapy engineering platforms designed to optimize cellular phenotypes for therapeutic applications.
- Notable investors include Fifty Years, MBX Capital.
- Status: Privately Held (backing).
Who backs Enoda Cellworks
2- ·Watch Enoda Cellworks: the Monday email on marks, rounds and moves
Enoda Cellworks funding rounds
No funding rounds for Enoda Cellworks are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
Enoda Cellworks investors
2 investors are on record for Enoda Cellworks, including Fifty Years and MBX Capital. By type, the record holds 2 venture capital firms.
About Enoda Cellworks
Developer of synthetic biology-based cell therapy engineering platforms designed to optimize cellular phenotypes for therapeutic applications. The company offers a platform that integrates molecular tooling, high-throughput screening, and systems immunology to precisely engineer cell types and functions tailored for specific indications, enabling biopharmaceutical developers and research institutions to create advanced cell therapies with improved efficacy and targeted disease-fighting capabilities.
- Sector
- Healthcare
- HQ
- Menlo Park, CA, United States
- Founded
- 2022
- Employees
- 7
- Website
- enoda.bio/
- Ownership
- Privately Held (backing)
Is this your company? Sign in with your work email to keep it current, or tell us what's wrong.
Enoda Cellworks doesn't have a valuation on record yet — one is published once a priced round, a reported valuation, fund marks, or secondary prints surface in our sources. The rest of the record below builds toward it.